PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
复制标题
DOI：
10.3390/cancers13215380
复制
发表时间：
2021-10-27
期刊：
影响因子：
5.2
通讯作者：
Orlandi E
中科院分区：
文献类型：
--
作者：
Barcellini A;Loap P;Murata K;Villa R;Kirova Y;Okonogi N;Orlandi E
尽管聚腺苷二磷酸核糖聚合酶(PARP-I)抑制剂的大量使用，但它们与放射治疗(RT)联合应用的可行性和安全性尚不清楚。在使用PARP-I治疗期间患者可能从局部放射治疗中受益的少转移瘤环境中，组合可能特别有趣。本综述的目的是评估PARP-I和RT联合治疗新诊断或复发肿瘤患者的结果和毒性。共有12项临床研究符合纳入标准，尽管评估的患者群体和肿瘤类型存在异质性，但这篇综述表明，即使疗效尚不清楚，联合方法也是可行的。背景：尽管聚腺苷二磷酸核糖聚合酶(PARP-I)抑制剂大量使用，但它们与放射治疗(RT)联合应用的可行性和安全性尚不清楚。目的：我们进行了文献分析，目的是评估RT和PARP-I联合应用的疗效和安全性。方法：根据人群、干预、控制、结果(PICO)标准，本综述的关键问题被表示为两个问题：1.结果是什么；2.对于新诊断或复发的肿瘤，PARP-I和RT联合治疗的患者的毒性是什么？结果：共有12项临床研究符合纳入标准，包括7项单臂剂量递增I期研究、2项II期(双臂和3臂对照试验)试验、1项平行臂I期研究和2项在2015-2021年间发表的I/II期研究。放射治疗采用光子束照射，根据临床情况选择不同的治疗方案。急性毒性≥3级介于25%和96%之间，分为血液学或非血液学不良事件。结论：尽管被评估的患者群体和肿瘤类型的异质性，以及研究的数量有限，但这篇综述表明，即使疗效尚不清楚，联合治疗也是可行的。
Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT during the treatment with PARP-I. The aim of the current review was to evaluate the outcome and the toxicity in patients with newly diagnosed or recurrent tumors treated with a combination of PARP-I and RT. A total of 12 clinical studies met the inclusion criteria and, despite the heterogeneity of the evaluated patient populations and tumor types, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.4103/0253-7184.69003
发表时间：
2010-01
影响因子：
0.4
作者：
Aslam S;Emmanuel P
通讯作者：
Emmanuel P
影响因子：
4.3
作者：
Helleday, T;Bryant, HE;Schultz, N
通讯作者：
Schultz, N
影响因子：
3.9
作者：
Mehta, Minesh P.;Wang, Ding;Curran, Walter J.
通讯作者：
Curran, Walter J.
影响因子：
3.4
作者：
Cesaire, Mathieu;Ghosh, Utpal;Chevalier, Francois
通讯作者：
Chevalier, Francois